RFI - GEIS Network Illumina Sequencing Platform Modernization
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), specifically the Global Emerging Infections Surveillance (GEIS) Branch, has issued a Request for Information (RFI) to identify commercial items for modernizing the GEIS Network's Illumina Sequencing Platform. This RFI seeks information on solutions, primarily the Illumina MiSeq i100 Plus Next-Generation Sequencing systems, to replace existing MiSeq (RUO), MiniSeq, and iSeq100 sequencers. The goal is to ensure continuity of global public health surveillance. Responses are due May 29, 2026, by 8:00 A.M. EST.
Scope of Information Sought
This RFI aims to ascertain whether a commercial item exists that provides the capabilities described in the attached RFI document. The primary focus is on the Illumina MiSeq i100 Plus system, particularly its onboard DRAGEN secondary analysis capabilities and the availability of room-temperature stable reagents. Information is sought regarding product availability, company information, and past performance, as detailed in Attachment 1. Attachment 2 outlines specific requirements for the MiSeq i100 Plus instruments, covering delivery, installation, training, service, reagents, and compliance with the Risk Management Framework (RMF).
Submission Details
Interested parties must submit white papers electronically via email to Jeffrey Sprecher (jeffrey.b.sprecher.civ@health.mil). Submissions should be in Microsoft Word or Adobe PDF format and must include a Cover Page, a Completed Attachment 1, and a Completed Attachment 2. The deadline for responses is May 29, 2026, by 8:00 A.M. EST.
Background & Rationale
The MiSeq i100 Plus is preferred due to its proprietary Illumina Sequencing by Synthesis (SBS) chemistry, which is crucial for data continuity and unique error profiles. Its integrated DRAGEN Bio-IT Platform is essential for performing secondary data analysis locally, enabling operations within secure, air-gapped environments and simplifying the RMF process. The requirement for room-temperature stable reagents is driven by logistical needs in austere, forward-deployed laboratories.
Important Notes
This RFI is for informational and planning purposes only and does not constitute a solicitation or a promise to issue a solicitation. The government will not accept offers or form a binding contract based on responses to this RFI. All responses will be treated as business-confidential. Responders are responsible for all associated costs, and no evaluation letters or results will be issued. Potential offerors should monitor SAM.gov for any future solicitation releases. No phone calls are requested.
Contact Information
For submissions and inquiries, contact Jeffrey Sprecher at jeffrey.b.sprecher.civ@health.mil.